Obgyn · Year 3 · from Obgyn

Case 2: Genitourinary Syndrome of Menopause

Patient Demographics

  • Age: 62 years
  • Sex: Female
  • Occupation: Retired nurse

Chief Complaint

"Sex has become too painful and I keep getting bladder infections."

History of Present Illness

The patient presents with a 3-year history of progressively worsening vaginal dryness and painful intercourse. She describes the pain as a burning and tearing sensation at the vaginal opening that persists for hours after intercourse. Over the past 18 months, she has had four documented urinary tract infections requiring antibiotic treatment. She reports urinary urgency, frequency (voiding 10 to 12 times daily), and occasional urgency incontinence with small-volume leakage. She also notes vaginal itching and occasional spotty discharge. She has tried over-the-counter lubricants with only minimal improvement. Her menopausal symptoms (hot flashes) resolved approximately 5 years ago. She has been postmenopausal for 12 years and never used hormone therapy. She is sexually active with her husband of 38 years and reports that the vaginal symptoms have significantly impacted their intimate relationship.

Past Medical History

  • Breast cancer, hormone receptor-positive, stage IA, diagnosed 6 years ago
  • Treated with lumpectomy and radiation followed by 5 years of anastrozole (aromatase inhibitor)
  • Completed anastrozole therapy 1 year ago
  • Hypertension, well-controlled
  • No history of VTE

Medications

  • Lisinopril 10 mg daily
  • Calcium 600 mg with vitamin D 800 IU twice daily

Physical Examination Findings

  • Vital Signs: BP 124/76 mmHg, HR 72 bpm, BMI 27 kg/m2
  • Breast: Well-healed lumpectomy scar right breast, no masses, no axillary nodes
  • External Genitalia: Significant labial atrophy with loss of subcutaneous fat, urethral meatus prominent and slightly erythematous
  • Vaginal Examination: Vaginal introitus narrowed, speculum insertion uncomfortable, vaginal mucosa pale, thin, dry with loss of rugae, petechiae visible on posterior vaginal wall, minimal clear discharge, pH 6.0 (elevated)
  • Bimanual Examination: Small atrophic uterus, ovaries not palpable, no adnexal tenderness

Diagnostic Workup

  • Vaginal pH: 6.0 (elevated; normal premenopausal 3.5-4.5)
  • Wet Mount: Parabasal cells predominant (consistent with atrophy), no trichomonads, no clue cells, no yeast
  • Urinalysis: Negative for infection currently
  • Post-Void Residual: 25 mL (normal)
  • Mammogram: BI-RADS 2, benign findings, 4 months ago

Diagnosis

Genitourinary Syndrome of Menopause (GSM) with:

  1. Vulvovaginal atrophy causing dyspareunia
  2. Urogenital atrophy contributing to recurrent UTIs
  3. Overactive bladder symptoms (urgency, frequency, urgency incontinence)

Special Consideration: History of hormone receptor-positive breast cancer requires careful discussion of low-dose vaginal estrogen risks and benefits

Management Plan

Discussion of Treatment Options:

Consideration in Breast Cancer Survivor:

  • Systemic hormone therapy is contraindicated due to history of hormone receptor-positive breast cancer
  • Low-dose vaginal estrogen remains controversial but data suggest:
  • Minimal systemic absorption with low-dose vaginal preparations
  • Serum estradiol levels remain in postmenopausal range
  • No clear evidence of increased breast cancer recurrence risk with low-dose vaginal estrogen
  • Decision should be individualized with oncology input

Stepwise Management Approach:

Step 1 - Non-hormonal therapies (first-line):

  1. Vaginal moisturizer (hyaluronic acid-based): Apply 3 times weekly to improve baseline tissue hydration
  2. Lubricant (silicone or water-based): Use liberally with intercourse
  3. Vaginal dilator therapy: Graduated dilators to maintain vaginal caliber and prevent further narrowing

Step 2 - If non-hormonal measures insufficient (after 8-12 weeks):

Option A - Low-dose vaginal estrogen (with oncology consultation):

  • Oncology consultation obtained; oncologist supportive of low-dose vaginal estrogen given completion of adjuvant therapy and significant quality of life impairment
  • Estradiol vaginal tablet (Vagifem) 10 mcg: Insert one tablet vaginally daily for 2 weeks, then twice weekly maintenance
  • Lowest effective dose with minimal systemic absorption

Option B - Non-estrogen hormonal option:

  • Intravaginal prasterone (DHEA) 6.5 mg nightly: Metabolized locally to estrogen and androgen; may be more acceptable to some breast cancer survivors
  • Ospemifene 60 mg orally daily: SERM with estrogen agonist effect on vaginal tissue; FDA-approved for moderate-to-severe dyspareunia; however, label warns about use in breast cancer survivors due to theoretical concerns

For Recurrent UTIs:

  1. Low-dose vaginal estrogen has been shown to reduce recurrent UTI risk by 50%
  2. If vaginal estrogen declined: vaginal probiotic (Lactobacillus) may help restore normal flora
  3. Consider prophylactic antibiotics if UTIs continue despite vaginal therapy

For Urinary Urgency/Frequency:

  1. Behavioral modifications: timed voiding, bladder training
  2. Pelvic floor physical therapy referral
  3. If vaginal estrogen improves tissue health, OAB symptoms often improve
  4. If persistent OAB: consider antimuscarinic medication

Follow-up Plan:

  1. Return in 8 weeks to assess response to initial non-hormonal therapy
  2. If insufficient improvement, initiate low-dose vaginal estrogen after informed consent and oncology clearance
  3. Annual mammography per oncology surveillance
  4. No routine monitoring of serum estradiol needed with low-dose vaginal preparations

Patient Counseling:

  • GSM is chronic and progressive without treatment
  • Non-hormonal options may provide partial relief
  • Low-dose vaginal estrogen is the most effective treatment
  • Systemic absorption with vaginal estrogen is minimal with approved low-dose preparations
  • Treatment will need to continue long-term as symptoms return upon discontinuation

Clinical Image

Image Description: Comparison diagram showing premenopausal estrogenized vaginal epithelium (thick, pink, rugated with normal pH 3.5-4.5) versus postmenopausal atrophic epithelium (thin, pale, smooth, with elevated pH above 5.0). The atrophic epithelium shows loss of superficial cells and predominance of parabasal cells on cytology.

Attribution: Educational diagram demonstrating vaginal epithelial changes in menopause. Similar to images available on Wikimedia Commons in Category:Menopause (https://commons.wikimedia.org/wiki/Category:Menopause).

All cases for this lecture as Markdown